



Kabra Drugs Limited

CIN NO : L02423MP1989PLC005438

Regd. Off : Shop No. 270, Shastri Market, Indore, Madhyapradesh. Phone : +91 98846 24100

To
BSE Limited
Phiroze Jeejeebhoy Towers
21st Floor, Dalal Street
Mumbai – 400 001

May 30, 2024

BSE Scrip Code: 524322

Sub.: Outcome of the Board Meeting and disclosure under Regulation 30 of SEBI(Listing Obligations & Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e 30th May 2024, inter-alia, considered and approved the following:

1. Audited financial results for the quarter and the year ended 31st March, 2024 In this regard, please find enclosed herewith the audited Financial Results along with Independent Auditors Report on Quarterly Financial Results of the Company pursuant to the Regulation 33 of SEBI (LODR) Regulations, 2015.
2. The Board discussed the compliance of the Statement of Deviation or Variation as per the Regulation 32 of SEBI (LODR) Regulations, 2015 and is of the view that the same is not applicable to company as the company has not issued any share by way of Public Issue, Right Issue, Preferential Issue etc. The undertaking of non-applicability of Regulation 32 of SEBI (LODR) Regulations, 2015 is enclosed herewith.
3. **Appointment of Secretarial Auditor:** Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 ("SEBI Listing Regulations), Anshu Chouhan & Associates, Practicing Company Secretaries (Mem No. A45198 and COP: 16531) are appointed as Secretarial Auditor of the Company to conduct Secretarial audit for the Financial Year 2023-24. Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 read with circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July, 2023 are attached as an Annexure-A & B.

The meeting of the Board of Directors of the Company commenced at 05.00 p.m. (IST) and concluded at 05:30 p.m. (IST).

Kindly take the above intimation on your records.

Thanking you,

Yours sincerely,

For Kabra Drugs Limited

B V Ananthkumar
Whole-time Director
DIN: 08644948



KABRA DRUGS LTD

CIN:- L02423MP1989PLC005438
Regd. Office: Shop No. 270, Shastri Market, Indore - 452001
Email:- kabradrugs@rediffmail.com

(Rs. In lacs)

Statement of Audited Standalone Financial Results for the Year Ended March 31, 2024

Sl no.	Particulars	Quarter Ended			Year Ended	
		31-Mar-24	31-Dec-23	31-Mar-23	31-Mar-24	31-Mar-23
	(Refer Notes Below)	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1	INCOME					
(a)	Revenue From Operation	-	-	-	-	-
(b)	Other Operating Income	-	-	-	-	0.64
	Total Income from Operations (Net)	-	-	-	-	0.64
2	EXPENSES					
(a)	Cost of material consumed	-	-	-	-	-
(b)	Changes in inventories of finished goods, work-in-progress, and stock-in-trade	-	-	-	-	-
(c)	Employee benefit expense	12.49	9.19	8.39	40.04	23.16
(d)	Finance Costs	-	-	-	-	-
(e)	Depreciation and amortization expense	-	-	-	-	-
(f)	Other expenses(Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	24.58	1.72	5.84	33.57	11.27
	Total Expenses	37.07	10.91	14.23	73.61	34.43
3	Profit / (Loss) from operations before exceptional items Tax (1-2)	(37.07)	(10.91)	(14.23)	(73.61)	(33.79)
4	Exceptional Items	-	-	-	-	-
5	Profit / (Loss) before Tax (3 ± 4)	(37.07)	(10.91)	(14.23)	(73.61)	(33.79)
6	Tax Expense	-	-	-	-	-
7	Net Profit / (Loss) after Tax (5 - 6)	(37.07)	(10.91)	(14.23)	(73.61)	(33.79)
8	Other Comprehensive Income (net of tax)	-	-	-	-	-
9	Total Comprehensive Income for the period (7 ± 8)	(37.07)	(10.91)	(14.23)	(73.61)	(33.79)
10	Paid-up equity share capital (Face Value of Rs.10/- each)	438.86	438.86	438.86	438.86	438.86
11	Other Equity	-	-	-	(585.57)	(511.96)
12	Earnings Per Share (of Rs. 10/- each) (not annualised):					
(a)	Basic	(0.84)	(0.25)	(0.32)	(1.68)	(0.77)
(b)	Diluted	(0.84)	(0.25)	(0.32)	(1.68)	(0.77)



KABRA DRUGS LTD

CIN:- L02423MP1989PLC005438

Regd. Office: Shop No. 270, Shastri Market, Indore - 452001

Email:- kabradrugs@rediffmail.com

(Rs. in Lakhs)

Standalone Statement of Assets and Liabilities		As at 31st March, 2024	As at 31st March, 2023
Particulars		Audited	Audited
A	ASSETS		
1	Non-current assets		
	Property, plant and equipment	-	-
	Capital work-in-progress	-	-
	Other intangible assets	-	-
	Investments in subsidiaries, associates and joint ventures	-	-
	Financial assets		
	Investments	-	-
	Loans	-	-
	Other financial assets	-	-
	Income Tax assets (net)	-	-
	Deferred tax assets (net)	-	-
	Other non-current assets	2.32	2.32
	Sub-total - Non-Current Assets	2.32	2.32
2	Current assets		
	Inventories	-	-
	Financial assets		
	Investments	-	-
	Trade receivables	60.05	60.05
	Cash and cash equivalents	11.65	0.15
	Bank balances other than Cash and Cash equivalents above	255.45	0.15
	Loans, Current	4.35	4.35
	Other financial assets	119.99	-
	Other current assets	3.34	3.34
	Assets classified as held for sale	-	-
	Sub-total - Current Assets	454.83	68.04
	TOTAL - ASSETS	457.15	70.36
B	EQUITY AND LIABILITIES		
1	Equity		
	Equity Share capital	438.86	438.86
	Other equity	(585.57)	(511.96)
	Share Application Money Received	255.00	-
	Sub-total - Shareholders' funds	108.29	(73.10)
2	LIABILITIES		
	Non-current liabilities		
	Financial liabilities		
	Borrowings, non-Current	-	-
	Provisions	-	-
	Income tax liabilities (net)	-	-
	Other non-current liabilities	-	-
	Sub-total - Non-current liabilities	-	-
3	Current liabilities		
	Financial liabilities		
	Borrowings, Current	170.84	138.19
	Trade payables, Current	-	-
	Other financial liabilities	172.75	-
	Other current liabilities	5.27	5.27
	Provisions	-	-
	Current tax liabilities (net)	-	-
	Sub-total - Current liabilities	348.86	143.46
	TOTAL - EQUITY AND LIABILITIES	457.15	70.36

(Signature)



KABRA DRUGS LTD

CIN:- L02423MP1989PLC005438

Regd. Office: Shop No. 270, Shastri Market, Indore - 452001

Email:- kabradrugs@rediffmail.com

Notes:

- 1 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on May 30, 2024.
- 2 The Statutory Auditors have carried out a limited review of the above financial result.
- 3 Company has only one segment and hence no separate segment result has been given.
- 4 The figure of previous period/year have been re-grouped / re-arranged and /or recast wherever found necessary.
- 5 This statement is as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015



By order of the Board
For, KABRA DRUGS LTD

A handwritten signature in blue ink, appearing to read "B V Ananthkumar".

B V Ananthkumar
Whole-time Director
DIN: 08644948

Place : Indore

Date : 30th May, 2024

KABRA DRUGS LTD

CIN:- L02423MP1989PLC005438

Regd. Office: Shop No. 270, Shastri Market, Indore - 452001


STANDALONE STATEMENT OF CASH FLOW

Particulars	As at 31st March, 2024	As at 31st March, 2023
	(Rs. In lacs)	(Rs. In lacs)
A. CASH FLOW FROM OPERATING ACTIVITIES:		
Profit before tax	73.61	33.79
Adjustment For :		
Share of (profit)/loss from investment in partnership firm	-	-
Depreciation/amortization on continuing operation	-	-
Loss on Sale of Fixed Assets	-	-
Operating profit before working capital changes	73.61	33.79
Movement in Working Capital :		
Increase/(decrease) in Inventory	-	-
Increase/(decrease) in Trade receivables	-	-
Increase/(decrease) in Short Term Loan & Advances	-	2.78
Increase/(decrease) in Current Liabilities	172.75	4.43
Increase/(decrease) in Trade Payable	-	-
Increase/(decrease) in Other Current Assets	119.99	-
Direct taxes paid (net of refunds)	-	-
Net Cash Flow from Operating Activities(A)	20.85	35.44
B. CASH FLOW FROM INVESTING ACTIVITIES		
Investments In Shares / withdrawal in Partnership Firm	-	-
Purchase / Sale of Fixed Assets	-	-
Interest Received	-	-
Change in Bank balances not considered as cash	-	-
Increase/(decrease) in Long Term Loan & Advances	-	-
Net Cash Flow from Investing Activities(B)	-	-
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceed (Repayment) from long term borrowing	-	-
Proceed (Repayment) from short term borrowing	32.65	35.61
Finance Cost	-	-
Proceed from Share Application Money	255.00	-
Net Cash Flow from Financing Activities(C)	287.65	35.61
Net increase/(decrease) in cash & cash equivalents(A+B+C)	266.80	0.17
Cash and Cash equivalents (Opening Balance)	0.30	0.13
Cash and Cash equivalents (Closing Balance)	267.10	0.30

Previous year figure have been regrouped/ reclassified wherever necessary

The above statement of cash flows has been prepared under the "Indirect Method" as set out in Ind AS - 7, "Statement of Cash Flows"





RISHI SEKHRI AND ASSOCIATES CHARTERED ACCOUNTANTS

GROUND FLOOR, BANDRA ARCADE BUILDING, OPP. RAILWAY STATION, BANDRA (WEST), MUMBAI - 400 050.
Tel.: 9820501848, Email : rishisekhri@gmail.com

Independent Auditor's Report on Audited Standalone Quarterly Financial Results 31.03.2024 and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To,
The Board of Directors Of
Kabra Drugs Limited

Report on the audit of the Standalone Financial Results

Opinion

We have audited the accompanying annual standalone financial results of **Kabra Drugs Limited** ("the company") for the quarter and year ended on 31/03/2024, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information for the quarter ended 31/03/2024 as well as the year to date results for the period from 01/04/2023 to 31/03/2024.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act,



2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Standalone Financial Results

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been compiled from the related audited Standalone Financial Statements. The Company's Board of Directors are responsible for the preparation and presentation of the Standalone Financial Results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Company in accordance with Indian accounting standards prescribed under section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations, as amended. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit.



We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For, Rishi Sekhri and Associates

Chartered Accountants

FRN: 128216W

CA Rishi Sekhri

Partner

MEMBERSHIP NO. 126656

Place: MUMBAI

Date: 30.5.2024

UDIN: 23126656BGWLLN6208





Kabra Drugs Limited

CIN NO : L02423MP1989PLC005438

Regd. Off : Shop No. 270, Shastri Market, Indore, Madhyapradesh. Phone : +91 98846 24100

To
The Deputy Gen. Manager,
Department of Corporate Services,
BSE Limited,
P J Tower, Dalal Street
Mumbai-400001.

30 May 2024

Ref: Scrip ID: KABRADG, Scrip Code: 524322

Subject: Declaration with respect to audit report with unmodified opinion for the financial year ended on March 31, 2024

Dear Sir,

In compliance with the provisions of Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended by SEBI Notification No. SEBI/LAD-NRO/GN/2016-17/001 dated May 25, 2016 and SEBI Circular No. CIR/CFD/CMD/56/2016 dated May 27, 2016, we hereby declare that the Auditor of our Company, M/s Rishi Sekhri and Associates Chartered Accountants, have issued an Auditors' Report with unmodified opinion on Audited Standalone Financial Results of the Company for the quarter and financial year ended March 31, 2024

Thanking You

Yours Faithfully,
For Kabra Drugs Limited



B V Ananthkumar
Whole-time Director
DIN: 08644948



Kabra Drugs Limited

CIN NO : L02423MP1989PLC005438

Regd. Off : Shop No. 270, Shastri Market, Indore, Madhyapradesh. Phone : +91 98846 24100

To
The Deputy Gen. Manager,
Dept.of Corporate Services,
BSE Ltd,
P.J. Tower, Dalal Street,
Mumbai – 400 001.

30 May 2024

Subject: Undertaking for Non-Applicability of Regulation 32 of SEBI (LODR) Regulations, 2015 for the quarter and year ended 31st March 2024.

As per Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the listed entity shall submit to the stock exchange the following statement(s) on a quarterly basis for public issue, rights issue, preferential issue etc.,-

- (a) Indicating deviations, if any, in the use of proceeds from the objects stated in the offer document or explanatory statement to the notice for the general meeting, as applicable;
- (b) Indicating category wise variation (capital expenditure, sales and marketing, working capital etc.) between projected utilization of funds made by it in its offer document or explanatory statement to the notice for the general meeting, as applicable and the actual utilization of funds.

In view of the aforesaid, I, the undersigned, Mr. B V Ananthkumar, Whole-time Director of Kabra Drugs Limited hereby certify that Compliances of Regulation 32 of SEBI (LODR) Regulations, 2015 is not applicable to the company as the company has not issued any share by way of public issue, right issue, preferential issue etc. for the quarter and year ended 31st March 2024.

For Kabra Drugs Limited

B V Ananthkumar
Whole-time Director
DIN: 08644948





Kabra Drugs Limited

CIN NO : L02423MP1989PLC005438

Regd. Off : Shop No. 270, Shastri Market, Indore, Madhyapradesh. Phone : +91 98846 24100

Annexure – A

Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July, 2023.

Sr. No.	Particulars	Details
1.	Reason for Change viz., appointment.	Appointment: to comply with the Companies Act, 2013 and the requirements under the SEBI (LODR) Regulations, 2015
2.	Date of Appointment/ cessation and terms of appointment	30 th may, 2024 Anshu Chouhan & Associates, Company Secretaries is appointed as Secretarial Auditor of the Company for the financial year 2023-24
3.	Brief profile (in case of appointment)	Please Refer Annexure B
4.	Disclosure of relationships between Directors (in case of appointment of a director).	None





Kabra Drugs Limited

CIN NO : L02423MP1989PLC005438

Regd. Off : Shop No. 270, Shastri Market, Indore, Madhyapradesh. Phone : +91 98846 24100

Annexure – B

PROFILE

<u>Name of the Firm</u>	Anshu Chouhan & Associates
<u>Name of the proprietor</u>	CS Anshu Chouhan
<u>Address</u>	A-19, Madhav Nagar, Behind Mahila Ashram College, Pathik nagar, 311001 (RJ.)
<u>Contact</u>	Phone No: 7733034200 Email: csanshuchouhan@yahoo.com
<u>Career Profile</u>	Over 8 years of post-qualification experience in the filed of secretarial and legal matter of various Companies. Exposure in handling Public, Right Issues, conducting AGMs, EGM's, Board Meetings. Secretarial Audits, Statutory Compliance with SEBI Regulations, FEMA, RBI, Company Law and related Acts.

